| Code | CSB-RA023978MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LBL-019, targeting TNFRSF1B (Tumor Necrosis Factor Receptor Superfamily Member 1B), also known as TNFR2 or CD120b. TNFRSF1B is a cell surface receptor that binds tumor necrosis factor-alpha (TNF-α) and plays a crucial role in regulating immune responses, cell survival, and inflammatory signaling. Unlike TNFRSF1A, which mediates pro-apoptotic signals, TNFRSF1B primarily promotes cell proliferation and tissue repair through NF-κB pathway activation. This receptor is particularly important in T regulatory cell function and has been implicated in various autoimmune diseases, inflammatory conditions, and cancer progression, where it can contribute to immune evasion and tumor growth.
As a biosimilar to the reference antibody LBL-019, this product provides researchers with a reliable tool for investigating TNFRSF1B biology and its therapeutic potential. It is suitable for studies exploring TNF signaling pathways, immune regulation mechanisms, and the development of targeted immunotherapies for autoimmune disorders and malignancies where TNFRSF1B expression is dysregulated.
There are currently no reviews for this product.